Regenxbio Inc (RGNX)
Healthcare
Biotechnology
9.70 $
-4.2%
vs. previous close
Closing price · As of: 31. Jul 2026
Who owns Regenxbio Inc (RGNX)? This page shows the largest institutions and funds, the ownership structure and the latest insider transactions. 83.2% of the shares are freely tradable; institutional investors hold 84.7%.
Ownership Structure
Institutional ownership
Share of the stock held by institutional investors (funds, banks, insurers) according to regulatory filings.
84.7%
Insiders
Share of the stock held by the executives, founders and major shareholders of the company itself.
8.1%
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
83.2%
Short % of float
Shares sold short as a percentage of the freely tradable float — high values signal many bets on falling prices.
19.3%
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
52Mio.
Largest Shareholders
Institutions
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| BlackRock Inc | 11.19 | 5,782,808 | +0.5 | 03/31/2026 |
| Redmile Group, LLC | 8.45 | 4,368,804 | +0.0 | 03/31/2026 |
| JPMorgan Chase & Co | 6.74 | 3,483,800 | -2.0 | 03/31/2026 |
| Vanguard Group Inc | 6.53 | 3,374,140 | +1.1 | 12/31/2025 |
| State Street Corp | 5.28 | 2,731,485 | +19.4 | 03/31/2026 |
| Morgan Stanley - Brokerage Accounts | 4.00 | 2,066,157 | +2.5 | 03/31/2026 |
| Vanguard Capital Management, LLC | 3.88 | 2,007,146 | +0.0 | 03/31/2026 |
| The Goldman Sachs Group Inc | 3.56 | 1,839,463 | +3.0 | 03/31/2026 |
| Integral Health Asset Management, LLC | 2.90 | 1,500,000 | +25.0 | 03/31/2026 |
Funds
| Name | Stake (%) | Shares | Change (%) | Date |
|---|---|---|---|---|
| State Street® SPDR® S&P® Biotech ETF | 2.94 | 1,519,007 | -0.6 | 05/31/2026 |
Largest reported positions according to regulatory filings; stake as a percentage of shares outstanding, change versus the previous filing. Source: fundamentals data.
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.